Literature DB >> 21606131

Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study.

S B Kjøtrød1, S M Carlsen, P E Rasmussen, T Holst-Larsen, J Mellembakken, A Thurin-Kjellberg, K Haapaniemikouru, L Morin-Papunen, P Humaidan, A Sunde, V von Düring.   

Abstract

BACKGROUND: To study the effect of metformin before and during assisted reproductive technology (ART) on the clinical pregnancy rate (CPR) in non-obese women with polycystic ovary syndrome (PCOS).
METHODS: A multi-centre, prospective, randomized, double-blind study was conducted in eight IVF clinics in four Nordic countries. We enrolled 150 PCOS women with a body mass index <28 kg/m(2), and treated them with 2000 mg/day metformin or identical placebo tablets for ≥ 12 weeks prior to and during long protocol IVF or ICSI and until the day of pregnancy testing. The primary outcome measure was CPR. Secondary outcome measures included spontaneous pregnancy rates during the pretreatment period, and the live birth rate (LBR).
RESULTS: Among IVF treated women (n = 112), biochemical pregnancy rates were identical in both groups (42.9%), and there were no significant differences in the metformin versus the placebo group in CPR [39.3 versus 30.4%; 95% confidence interval (CI): -8.6 to 26.5]. The LBR was 37.5 versus 28.6% (95% CI: -8.4 to 26.3). However, prior to IVF there were 15 (20.3%) spontaneous pregnancies in the metformin group and eight (10.7%) in the placebo group (95% CI: -1.9 to 21.1; P = 0.1047). According to intention to treat analyses (n = 149); significantly higher overall CPR were observed in the metformin versus placebo group (50.0 versus 33.3%; 95% CI: -1.1 to 32.3; P = 0.0391). LBR was also significantly higher with use of metformin versus placebo (48.6 versus 32.0; 95% CI: 1.1 to 32.2; P = 0.0383). No major unexpected safety issues or multiple births were reported. More gastrointestinal side effects occurred in the metformin group (41 versus 12%; 95% CI: 0.15 to 0.42; P < 0.001).
CONCLUSIONS: Metformin treatment for 12 weeks before and during IVF or ICSI in non-obese women with PCOS significantly increases pregnancy and LBRs compared with placebo. However, there was no effect on the outcome of ART per se. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00159575.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606131     DOI: 10.1093/humrep/der154

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  16 in total

1.  Metformin use in patients undergoing in vitro fertilization treatment: results of a worldwide web-based survey.

Authors:  Mindy S Christianson; Harold Wu; Yulian Zhao; Matan Yemini; Milton Leong; Zeev Shoham
Journal:  J Assist Reprod Genet       Date:  2015-01-30       Impact factor: 3.412

Review 2.  Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.

Authors:  Leopoldo O Tso; Michael F Costello; Luiz Eduardo T Albuquerque; Régis B Andriolo; Cristiane R Macedo
Journal:  Cochrane Database Syst Rev       Date:  2014-11-18

3.  The Pregnancy in Polycystic Ovary Syndrome II study: baseline characteristics and effects of obesity from a multicenter randomized clinical trial.

Authors:  Richard S Legro; Robert G Brzyski; Michael P Diamond; Christos Coutifaris; William D Schlaff; Ruben Alvero; Peter Casson; Gregory M Christman; Hao Huang; Qingshang Yan; Daniel J Haisenleder; Kurt T Barnhart; G Wright Bates; Rebecca Usadi; Richard Lucidi; Valerie Baker; J C Trussell; Stephen A Krawetz; Peter Snyder; Dana Ohl; Nanette Santoro; Esther Eisenberg; Heping Zhang
Journal:  Fertil Steril       Date:  2013-10-21       Impact factor: 7.329

4.  Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome.

Authors:  Abigail Sharpe; Lara C Morley; Thomas Tang; Robert J Norman; Adam H Balen
Journal:  Cochrane Database Syst Rev       Date:  2019-12-17

5.  Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.

Authors:  Leopoldo O Tso; Michael F Costello; Luiz Eduardo T Albuquerque; Regis B Andriolo; Cristiane R Macedo
Journal:  Cochrane Database Syst Rev       Date:  2020-12-21

6.  A possible role for AMP-activated protein kinase activated by metformin and AICAR in human granulosa cells.

Authors:  Yufuko Kai; Yasushi Kawano; Hanae Yamamoto; Hisashi Narahara
Journal:  Reprod Biol Endocrinol       Date:  2015-04-10       Impact factor: 5.211

7.  Metformin inhibits follicle-stimulating hormone (FSH) action in human granulosa cells: relevance to polycystic ovary syndrome.

Authors:  Suman Rice; Androulla Elia; Zara Jawad; Laura Pellatt; Helen D Mason
Journal:  J Clin Endocrinol Metab       Date:  2013-07-11       Impact factor: 5.958

Review 8.  Epidemiology, diagnosis, and management of polycystic ovary syndrome.

Authors:  Susan M Sirmans; Kristen A Pate
Journal:  Clin Epidemiol       Date:  2013-12-18       Impact factor: 4.790

9.  Effects of Metformin Treatment on Homocysteine Levels and Metabolic Parameters of Women With Polycystic Ovary Syndrome.

Authors:  Soheila Riahinejad; Ahmad Mirdamadi; Elham Alizadeh
Journal:  J Family Reprod Health       Date:  2015-11

10.  The function of metformin in endometrial receptivity (ER) of patients with polycyclic ovary syndrome (PCOS): a systematic review and meta-analysis.

Authors:  Lifang Yuan; Hongbo Wu; Weiyu Huang; Yin Bi; Aiping Qin; Yihua Yang
Journal:  Reprod Biol Endocrinol       Date:  2021-06-14       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.